J P M O R G A N North America Equity Research 13 August 2026 Ascendis Pharma Yorvi & Yuvi Looking Good; Initial Take on 2Q ASND delivered an impressive 2Q print, noting consistent demand for Yorvipath, reaching >220 unique pt enrollments for Yuviwel thru July 31, and clicking over to net profitability after a few quarters of operating profitability, even excluding the PRV sale in the qtr. Total product revenues came in at €315mm up 105% YOY and beat JPMe/company-compiled cons of €298mm/€304mm, supported by ...